Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.2414-2415
Main Authors: Liu, Fei Fei, Subbiah, Krishnaveni, Gu, Tao, Le, Trong Kim
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-162587